• TG Therapeutics recently reported past first-quarter 2026 results showing revenue of US$204.92 million and net income of US$19.78 million, while raising its full-year 2026 total global revenue target to about US$925 million, largely driven by higher expected BRIUMVI U.S. net product revenue of US$885 million to US$900 million.
• This combination of stronger earnings and higher guidance underlines how central BRIUMVI has become to TG Therapeutics’ business model and forward planning.
• We’ll now examine how the upgraded 2026 BRIUMVI revenue guidance could reshape TG Therapeutics’ existing investment narrative and risk profile.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics today, you need to believe BRIUMVI can keep scaling while the company manages its dependence on a single drug and payer pressure on pricing. The stronger Q1 2026 results and higher full year revenue target reinforce BRIUMVI as the key short term catalyst, while also amplifying the main risk that any disruption to this product could have an outsized impact. On balance, this news strengthens the existing catalyst without fundamentally changing the core risk profile.

The most relevant update alongside this guidance hike is TG’s Q2 2026 target of about US$220 million in BRIUMVI U.S. net product revenue, which directly connects near term execution to the upgraded full year outlook. That quarterly marker gives investors a concrete checkpoint for how quickly BRIUMVI is scaling and how realistic the new US$885 million to US$900 million U.S. BRIUMVI target may be, especially with the subcutaneous formulation still working through Phase 3 development.

Yet, despite this upbeat guidance, investors should still be aware that…

Read the full narrative on TG Therapeutics (it’s free!)

TG Therapeutics’ narrative projects $1.5 billion revenue and $461.7 million earnings by 2029.

Uncover how TG Therapeutics’ forecasts yield a $44.43 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming BRIUMVI could help lift annual revenue toward about US$1.5 billion and earnings to roughly US$654 million, so this new guidance may either support or challenge those expectations depending on how you view the risk of pricing pressure and payer pushback on high cost therapies.

Explore 7 other fair value estimates on TG Therapeutics – why the stock might be worth less than half the current price!

The Verdict Is Yours

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate TG Therapeutics’ overall financial health at a glance.

No Opportunity In TG Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com